Skip to content
Notification Image

Important! APA's Online Systems Updated.

Password reset will be required.

Read more here >

PCSS Webinars

The Providers Clinical Support System (PCSS) is comprised of a coalition of major healthcare organizations dedicated to addressing the opioid overdose crisis. PCSS's mission is to increase healthcare providers' knowledge and skills in the prevention, identification and treatment of substance use disorders with a focus on opioid use disorders.

As a PCSS partner, APA offers webinars presented by nationally recognized clinical experts, researchers and government officials so clinicians have access to the latest evidence-based practices for effective treatment options for their patients.

Archived versions of the recorded webinars are made available with or without CME credit through the APA Learning Center. CME is offered free of charge. View the list of available archived webinars below.

The available archived webinars are displayed below by year of presentation.

2022

HIV and Substance Use – Intertwined Epidemics

The epidemics of HIV disease and substance use are mutually-reinforcing, and both involve significant morbidity. People with HIV and SUDs have worse health-related outcomes than those with HIV alone. The webinar will review the epidemiology of HIV and substance use, and address the structural and social factors that affect individual risk, particularly within marginalized communities.

  • February 8, 2022
  • Michael Polignano, M.D.

Preventing Suicide in People with Opioid Use Disorder

This webinar reviews the complex relationships between substance misuse and suicide, with a focus on opioid use disorder (OUD). This category is associated with a significant elevation of suicide risk and premature mortality. Methodological challenges in detecting drug poisoning suicides are reviewed along with emerging clinical data that suggest treatment seeking OUD patients who have survived non-fatal opioid overdose report desire and intention to die prior to overdose.

  • January 11, 2022
  • Hillary S. Connery, M.D., Ph.D.

2021

Treatment of Opioid Use Disorder in the ED: Should it be a Choice?

The webinar delivers critical information to help learners evaluate outcomes for Opioid Use Disorder in patients receiving buprenorphine through the emergency department, as well as barrier to initiating buprenorphine in this setting. Since buprenorphine is such a strong medication, there are components to the integration pathway which much be addressed when receiving consent to treat Opioid Use Disorder.

  • April 13, 2021
  • Gail D’Onofrio, M.D.

Methamphetamine in the Era of Fentanyl: Toxicities and Pharmacotherapies

This webinar provides an intermediate level review of morbidity and mortality trends related to methamphetamine, as well as the differences between non-fatal and fatal acute methamphetamine toxicity. It introduces evidence-based supporting interventions for treating methamphetamine use specifically, as well as extrapolating treatment methods for other substances common to addiction.

  • March 9, 2021
  • Phillip Coffin, M.D., M.I.A., F.A.C.P., F.I.D.S.A.

Racial Inequities in Substance Use

This activity summarizes the racism inequities and their relationship to substance use treatment. It also dives into the federal and state policies and how inequities in law has led to the criminalization of substance use. Finally, the webinar provided strategies for assessing substance use disorder and subsequently producing a treatment plan, specifically for racial and ethnic minorities.

  • February 9, 2021
  • Michelle Durham, M.D., M.P.H., F.A.P.A., D.F.A.A.C.A.P.

Clinical and Public Health Interventions to Address the Overdose Crisis

This activity reviews the expanding overdose crisis and the different opportunities to engage high risk individuals. Evidence-based practice will be discussed including: overdose education and how to use naloxone rescue kits, medication for opioid use disorder, and prescription opioid safety.

  • January 12, 2021
  • Alexander Walley, M.D., M.Sc.

2020

Integrating Hepatitis C Care into your MAT Clinic

This webinar provides an overview of the evidence of medications for OUD (MOUD) such as buprenorphine or methadone, as an effective preventative method against blood-borne viruses commonly associated with injection opioid use such as hepatitis C virus (HCV). This activity will highlight the impact of applying the HCV care continuum on the treatment outcomes for OUD patients with comorbid infections. Best practices on how to effectively interact and talk with psychiatric patients about their substance use and how MAT can act as an effective co-prevention method for HCV infection.

  • November 10, 2020
  • Yavar Moghimi, M.D.

Medications for OUD and Criminal Justice Systems and Settings

This activity will describe recent trends in criminal justice system (CJS) populations and intersections with the US opioid epidemic, detail clinical trials examining the application of medications for OUD treatment in CJS populations and give context to recent and proposed policies impacting CJS and opioid use disorders.

  • October 13, 2020
  • Joshua D. Lee, M.D.

Mindfulness for Chronic Pain and Opiate Dependence

This webinar, presented by faculty expert, Dr. Ronald Siegel, will introduce a step-by-step, mind-body approach that integrates advances in rehabilitation medicine with psycho-dynamic, behavioral, and mindfulness-based techniques. This activity will supply practitioners with the tools to help patients interrupt the cognitive, affective, and behavioral components of chronic pain cycles, using mindfulness practices to increase symptom tolerance, reduce pain-related anxiety, and engage more fully in life activities, reducing their dependence on analgesic medications. We will explore how these same practices and principles can help interrupt the cycles that maintain opiate dependence. By the end of this activity, participants will gain a greater appreciation for mindfulness methods and their possible efficacy in addressing persistent, chronic pain in patients with comorbid opiate dependencies and similar substance use behavior patterns.

  • September 8, 2020
  • Ronald Siegel, Psy.D.

Recovery Supports for Young People with Opioid Use Disorders

Adolescents and young adults may display vastly different behaviors of substance use disorders. Their brains are still in development and therefore the exhibition of substance use patterns of behavior may not be as easily recognizable when compared to their older adult counterparts. This webinar intends to highlight that medication for opioid use treatment is a key component of their recovery. However, this presentation will equip providers with additional support plan models to implement within their practices, including a reduction in reliance on office-setting care and a greater emphasis on family-based, school-based programs and mutual peer support help organizations.

  • July 14, 2020
  • Amy Yule, M.D.

Mental Health and OUD: Working with LGBTQ+ Individuals

Substance use disorders and opioid use disorders are more common in LGBTQ individuals with comorbid mental illness. In addition, many treatment programs do not have the culturally sensitive resources to adequately treat LGBTQ patients and are not aware of resources available for those who may have other underlying conditions or adverse histories. Micro-aggressions and discrimination in MAT practice can negatively impact treatment and recovery from substance use disorders, therefore it is essential for practitioners to have a greater understanding of this minority population.

  • June 9, 2020
  • Petros Levounis, MD

The Intersection of Problematic Gambling and Opioid Use Disorder

Problematic gambling and gambling disorder are common and more common in individuals with substance use disorders, especially those with opioid use disorder. In addition, many treatment programs do not screen patients for problematic gambling and are not aware of resources available for those who screen positive. Underlying problematic gambling can cause complications in and of itself or can negatively impact treatment and recovery from other substance use disorders. Clinicians can learn to screen individuals and provide them with useful resources.

  • April 14, 2020
  • Christopher Welsh, M.D.

Long-acting Buprenorphine Treatment for Opioid Use Disorder

Lack of knowledge about available long-acting buprenorphine formulations has led their under-utilization in the health care system, despite large unmet treatment needs among those with opioid use disorder. A multi-disciplinary approach that includes the collaboration between nurse practitioners, PAs, physicians, psychologists, social workers and hospital administrators is necessary to address this gap in knowledge and provide evidence-based care to those with opioid use disorder. Several newly approved long-acting buprenorphine formulations give patients and providers new options to consider. This webinar will review the peer-reviewed publications from three FDA-approved long-acting products, their FDA-approved indications, practical information on how to use them in clinical practice, ongoing NIDA clinical trials employing these long-acting medications, and patient case scenarios.

  • February 11, 2020
  • Dr. Michelle Lofwall, M.D., DFASAM

The Connection between Mental Health and Opioid Use Disorder

There is a high prevalence of mental health disorders among those with opioid use disorder. However, many practitioners still find it difficult to distinguish between differential diagnoses that may have similar symptomatology, especially regarding mental health and substance misuse. This webinar will enable participants to summarize the prevalence of common co-morbid mental illness, explain the relationships between concurrent mental health and opioid use disorder (OUD) and recognize risk factors associated with both mental health disorders and OUD.

  • January 14, 2020
  • Dr. Mark Duncan, M.D.

2019

Vaccines for Opioid Use Disorder: Focusing on the Fentanyl Epidemic

Fentanyl has been the leading cause of opioid overdoses during the last couple of years, and these overdoses are not prevented by methdone, buprenorphine or naltrexone treatment. A vaccine against fentanyl has been able to block fentanyl's analgesic, reinforcing respiratory effects in animal models, and is moving forward FDA approval to be tested in humans. This webinar will discuss the mechanism of acting for fentanyl vaccines in preventing overdoses and abuse through the production of anti-fentanyl antibodies.

  • May 28, 2019
  • Thomas Kosten, M.D. & Fang Yang, M.D.

The Clinical and Public Health Utility of Mutual Aid Organizations in Addressing Addiction: What Does the Science Tell Us?

This activity will present results from comprehensive, gold-standard, reviews of the scientific clinical literature, investigate the health care cost savings obtainable by implementing mutual-aid facilitation approaches in clinical settings, and discuss the implications for clinical practice, addiction treatment and public health broadly.

  • April 23, 2019
  • John F. Kelly, Ph.D.

Tracking Drug Use Patterns

This presentation will enable participants to better identify drug use patterns across the United States and subsequent treatment responses to some of these emerging drug trends. They will additionally identify more efficacious responses for these trends and for drugs that are often understudied.

  • March 26, 2019
  • Jane C. Maxwell, Ph.D.

Rethinking Withdrawal Management: Expanding the Use of Outpatient Settings

This presentation will challenge participants to rethink outpatient withdrawal management. An outpatient setting for the treatment of withdrawal symptoms is safe and effective for most patients with substance use disorders. The chief advantage over treatment in an inpatient setting is higher likelihood of patient participation in meaningful follow up treatment. This presentation will highlight hybrid protocols frequent withdrawal concerns, thus arming psychiatrists and allied health professionals with effective, evidence based information to treat patients with substance use disorder in outpatient settings.

  • February 26, 2019
  • George Kolodner, M.D.

Telepsychiatry's Role in Medication Assisted Treatment

This webinar will explore how telepsychiatry can play a critical role in addressing the shortage of psychiatrists available to provide treatment for patients with opioid use disorders. Participants will learn from one of the experts in the field, Dr. Hector Colon-Rivera, regarding how telepsychiatry is being used to address unmet needs in underserved communities. The history of telepsychiatry, state laws, and standards and guidelines will be covered to enhance your understanding of foundational issues to implementing telepsychiatry in your community. Learning more about telepsychiatry could help vastly improve the treatment options for those who have limited access to care. Bridging the gaps in care for patients with opioid use disorders is another step to address the epidemic that is currently plaguing our nation.

  • January 29, 2019
  • Hector Colon-Rivera, M.D.

2018

Medication Assisted Treatment in the Emergency Room Setting

Opioid use disorder (OUD) is a rapidly growing and increasingly deadly national health crisis. Evidence is consistently pointing to the use of medication assisted treatment (MAT) as a critical element to a comprehensive treatment approach. VA Connecticut began an initiative to increase access to MAT for veterans by initiating MAT in the emergency room setting. This presentation will begin by setting the stage of OUD and will then review the methods and approach for the initiation of MAT in the ER setting. Finally, case examples will be reviewed to demonstrate the approach.

  • December 18, 2018
  • Brian Fuehrlein, M.D.

Recovery Support for Young People with Opioid Use Disorders

This presentation will review recovery supports in addition to medication that can be considered as part of the treatment plan for a young people with an opioid use disorder. These treatment components include: family involvement, school-based recovery programs, and mutual help groups.

  • November 27, 2018
  • Amy Yule, M.D.

Motivational Interviewing: Brushing up on the Basics

This webinar reviews the basic concepts and skills of Motivational Interviewing (MI) and employs MI skills and tools to illustrate the practical applicability of such tools in clinical practice for addiction and other patient populations.

  • September 25, 2018
  • Carla Marienfeld, M.D.

Expanding Access to Medication Assisted Treatment for Opioid Use Disorders to Patients in the Hospital

This presentation provides an overview of the opioid epidemic and the laws and regulations that dictate how medication assisted treatment can be used in the treatment of OUD, and discusses the exceptions to regulations that allow providers to use medication to treat OUD in patients seen in the emergency department or admitted to the hospital.

  • August 28, 2018
  • Christopher Welsh, M.D.

Main Results and Clinical Implications of the X:BOT Trial: XR-Naltrexone vs. Buprenorphine-Naloxone Film

This webinar examines the largest evaluation to date of extended-release naltrexone (XR-NTX) opioid treatment compared to buprenorphine maintenance, and discusses the relevance of the data to clinical practice.

  • July 31, 2018
  • Joshua D. Lee, M.D.

2017

Motivational Interviewing for Clinical Practice

The webinar will provide a clear presentation of Motivational Interviewing that is readily transferable to everyday clinical practice.

  • May 9, 2017
  • Petros Levounis, M.D., M.A.; Carla Marienfeld, M.D.; Bachaar Arnaout, M.D.

The Seeking Safety Model: Empirical and Clinical Developments

Seeking Safety is an evidence-based counseling model designed for trauma and/or addiction. This presentation will describe the model briefly, and offer a summary of new findings and clinical expansions.

  • April 24, 2017
  • Lisa Najavits, Ph.D.

Treating Substance Use Disorder Through Collaborative Care

Collaborative care is an evidence-based model of integrated mental health in primary care settings that shows clear and significant effectiveness for the treatment of depression, anxiety, and PTSD. Widespread implementation of Collaborative Care is now occurring across the country to answer the need for increased access for mental health treatment. Concurrently, there is a growing need for the treatment of substance use disorders, which often present in the primary care setting where they have traditionally been inadequately addressed.

  • April 4, 2017
  • Mark Duncan, M.D.

2016

Addiction, Overdose, and Suicide: Preventing Deaths From Drug Self-Intoxication

This webinar will review the proposed death sub-category, “death from drug self-intoxication,” as a surveillance strategy for improving accurate detection of a preventable death. Clinical translations of this concept, including empirical opportunities to elicit self-harm/suicide risk and to intervene with patients and families seeking treatment in a variety of clinical practice settings, will be presented.

  • June 21, 2016
  • Ian Rockett, Ph.D., M.P.H.; Hilary Connery, M.D., Ph.D.

Improving MAT Access and Quality through Collaborative Care: The CoOP Model

This session will describe a model of care, “Collaborative Opioid Prescribing (CoOP),” that links opioid treatment programs (OTPs) expertise with office-based buprenorphine (OBB) prescribers.

  • June 14, 2016
  • Kenneth B. Stoller, M.D.

Beyond Symptom Management: Mindfulness for Chronic Pain

This webinar will introduce a step-by-step, mind-body approach that integrates advances in rehabilitation medicine with psychodynamic, behavioral, and mindfulness-based techniques.

  • June 1, 2016
  • Ronald D. Siegel, Psy.D

Evidence-Based Treatment of Alcohol Use Disorder

This session will discuss the evidence showing that addiction produces changes in the brain; summarize NIH-funded research on medication assisted treatment; Review the FDA-approved medications for alcoholism as well as the cost benefits; Discuss some of the reasons given for non-prescription of relapse prevention medication and compare health benefits to other treatments.

  • May 10, 2016
  • Charles O’Brien, M.D.

Medical leadership for mind, brain and body.

Join Today